MDxHealth SA
NASDAQ:MDXH
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| BE |
M
|
MDxHealth SA
NASDAQ:MDXH
|
179.2m USD |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
389.4B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
197B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
193.8B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
116.6B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
82.4B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
74.1B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
43B EUR |
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
Market Distribution
| Min | -13 700% |
| 30th Percentile | 1.5% |
| Median | 7.4% |
| 70th Percentile | 14.7% |
| Max | 97 950% |
Other Profitability Ratios
MDxHealth SA
Glance View
MDxHealth SA engages in the development and commercialization of molecular diagnostic products for personalized cancer treatment. The company is headquartered in Herstal, Liege. The company went IPO on 2006-06-26. The Company’s tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, as well as prediction of response to a specific therapy. Its tests include ConfirmMDx for Prostate Cancer, SelectMDx for Prostate Cancer, PredictMDx for Glioblastoma and AssureMDx for Bladder Cancer. The firm's corporate operations are based in Herstal, Belgium, as well as Irvine, the United States, and its laboratory operations are based in Nijmegen, the Netherlands, as well as Irvine, the United States.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for MDxHealth SA is -34.4%, which is above its 3-year median of -58.6%.
Over the last 3 years, MDxHealth SA’s Net Margin has increased from -118.9% to -34.4%. During this period, it reached a low of -118.9% on Dec 31, 2022 and a high of -34.4% on Sep 30, 2025.
